AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00030849
Drug: bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04592666
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the standard therapy of single agent almonertinib
Trial: NCT04592666
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: standard dose
Trial: NCT04592666
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=5
Trial: NCT02544607
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5mg/kg over 40 minutes IV
Trial: NCT01326611
Drug: Dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01580501
Drug: Tadalafil and Sildenafil
RxNorm normalized name: finasteride and tadalafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
Trial: NCT02541604
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
Trial: NCT01438827
Drug: Avanz Phleum pratense
RxNorm normalized name: Phleum pratense top
DrugBank: Phleum pratense top (DB14179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for Injection, Every 6 weeks for one year
Trial: NCT00993148
Drug: maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg tab by mouth once daily for 96 weeks
Trial: NCT00993148
Drug: darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 800 mg tab by mouth once daily for 96 weeks
Trial: NCT00993148
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg capsule by mouth once daily for 96 weeks
Trial: NCT03971422
Drug: Rozanolixizumab
RxNorm normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Trial: NCT01237769
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2200 IU/day
Trial: NCT03287908
Drug: AMG 701
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IV infusions of AMG 701.
Trial: NCT03287908
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive oral capsules of pomalidomide.
Trial: NCT03287908
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive IV injections or oral dexamethasone.
Trial: NCT05993299
Drug: Letetresgene autoleucel
RxNorm normalized name: Letetresgene autoleucel
DrugBank: Letetresgene autoleucel (DB17233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letetresgene autoleucel will be administered.
Trial: NCT05993299
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Trial: NCT02970162
Drug: Amifampridine Phosphate
RxNorm normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04673396
Drug: Norcantharidin Lipid Microsphere for Injection
RxNorm normalized name: guggul lipids
DrugBank: Cantharidin (DB12328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Trial: NCT04673396
Drug: Sodium Demethylcantharidate Injection
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Trial: NCT02905890
Drug: Norethisterone enantate
RxNorm normalized name: Norethisterone enantate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
Trial: NCT03991520
Drug: Anakinra 100Mg/0.67Ml Inj Syringe
RxNorm normalized name: ANAKINRA 100MG/0.67ML INJ SYRINGE
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
Trial: NCT01940731
Drug: Colistimethate sodium
RxNorm normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
Trial: NCT03401502
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, b.i.d
Trial: NCT02029898
Drug: sodium chloride 0,9%
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03603262
Drug: SH-1028
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
Trial: NCT00806819
Drug: Nintedanib (BIBF1120)
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Trial: NCT00806819
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Trial: NCT00806819
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Trial: NCT00806819
Drug: B12
RxNorm normalized name: PB127
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
Trial: NCT01035021
Drug: use of rocuronium when the LMA is inserted
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
Trial: NCT02569502
Drug: enfuvirtide
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
Trial: NCT00806819
Drug: dexamethasone (or corticosteroid equivalent)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
Trial: NCT01317199
Drug: Muscadine Plus Grape Skin Extract
RxNorm normalized name: muscadine grape extract
DrugBank: Grape (DB10533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
Trial: NCT01317199
Drug: Low-dose MPX
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
Trial: NCT02484209
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1500 mg daily for 16 weeks
Trial: NCT02484209
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride 2-4 mg twice daily for 16 weeks
Trial: NCT02484209
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 1500 mg daily for 16 weeks
Trial: NCT01651637
Drug: synthetic surfactant (CHF5633)
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
Trial: NCT01996761
Drug: porcine brain peptide (Cerebrolysin)
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02831972
Drug: AG120
RxNorm normalized name: Ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02831972
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00829504
Drug: Ropinirole HCl 0.25 mg Tablets
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 0.25 mg
Trial: NCT02876601
Drug: Defibrotide
RxNorm normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6.25mg/kg bodyweight over 2h infusion
Trial: NCT02876601
Drug: Lipopolysaccharide
RxNorm normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus infusion of 2ng/kg bodyweight lps
Trial: NCT04273035
Drug: Midazolam oral solution
RxNorm normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Buccolam
Trial: NCT00357682
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg per day
Trial: NCT00357682
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg per day
Trial: NCT00357682
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg per day
Trial: NCT04436497
Drug: Zilucoplan
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily
Trial: NCT02064582
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160mg by mouth each day
Trial: NCT02064582
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
Trial: NCT01590888
Drug: PBT2
RxNorm normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg capsules administered orally once per day for 26 weeks
Trial: NCT01590888
Drug: PBT2
RxNorm normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg capsules administered orally once per day for 26 weeks
Trial: NCT01065077
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 150 µg/h during 48h
Trial: NCT01065077
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 100 µg/h during 48h
Trial: NCT01065077
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 50 µg/h during 48h
Trial: NCT04099589
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/Cisplatin plus Toripalimab
Trial: NCT03358017
Drug: Zoledronate
RxNorm normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg i.v. every 3/4 weeks for 6 months
Trial: NCT03358017
Drug: Atorvastatin 80mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg /die os for 6 months
Trial: NCT02160223
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
Trial: NCT02160223
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
Trial: NCT05110118
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single intravenous injection
Trial: NCT04124302
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Trial: NCT04124302
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Trial: NCT01937832
Drug: Faropenem
RxNorm normalized name: Faropenem
DrugBank: Faropenem (DB12190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: Injection dosage:1200 mg frequency: Three times a day
Trial: NCT01937832
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dosage form: Injection dosage:1000 mg frequency: once a day
Trial: NCT04124302
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Trial: NCT00072982
Drug: fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
Trial: NCT01148979
Drug: Lisdexamfetamine Dimesylate (Vyvanse)
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Trial: NCT00072982
Drug: combination fish oil and borage seed oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
Trial: NCT01132027
Drug: Tacrolimus Capsules
RxNorm normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
Trial: NCT01748162
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Trial: NCT00777153
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day, oral, until progression
Trial: NCT00777153
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day, oral, until progression
Trial: NCT00777153
Drug: Lomustine Chemotherapy
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 110 mg/m2 / Q6W, oral, until progression
Trial: NCT00777153
Drug: Placebo Cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, until progression
Trial: NCT03653507
Drug: zolbetuximab
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab were administered as a minimum 2-hour IV infusion.
Trial: NCT03653507
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin were administered as a 2-hour IV infusion.
Trial: NCT00895206
Drug: individual adapted immunosuppression
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: individual adapted immunosuppression
Trial: NCT00895206
Drug: golden standard therapy
RxNorm normalized name: GOLDEN SEAL
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golden standard therapy
Trial: NCT01516541
Drug: dalcetrapib
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg orally daily
Trial: NCT00554216
Drug: VI-0521
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg phentermine/23 mg topiramate
Trial: NCT00554216
Drug: VI-0521
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg phentermine/92 mg topiramate
Trial: NCT00554216
Drug: Placebo matched phentermine/topiramate
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo matched phentermine/topiramate
Trial: NCT04463459
Drug: Vitamin C, Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
Trial: NCT01933568
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combined CFRT and SABR with concurrent cisplatin
Trial: NCT00990704
Drug: paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Trial: NCT00990704
Drug: maxacalcitol
RxNorm normalized name: Maxacalcitol
DrugBank: Maxacalcitol (DB06272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Trial: NCT03851562
Drug: Alprostadil 20 micrograms
RxNorm normalized name: alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of PGE1 (Days 0, +1 and +2)
Trial: NCT01819012
Drug: Isoflurane 1.0 MAC
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 min-inhalation of each concentration of isoflurane, 1.0 MAC
Trial: NCT01819012
Drug: Isoflurane 1.5 MAC
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 min-inhalation of each concentration of isoflurane, 1.5 MAC
Trial: NCT01819012
Drug: Isoflurane 2.0 MAC
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 min-inhalation of each concentration of isoflurane, 2.0 MAC
Trial: NCT00913952
Drug: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions
RxNorm normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913952
Drug: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
RxNorm normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913952
Drug: Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
RxNorm normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00283621
Drug: Aranesp (darbepoetin alfa)
RxNorm normalized name: darbepoetin alfa Injection [Aranesp]
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00283621
Drug: Neulasta (pegfilgrastim)
RxNorm normalized name: pegfilgrastim Injection [Neulasta]
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00283621
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00283621
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04675008
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis